Evgeniy Vasilievich Papichev

Scopus Publications

CLINICAL AND DIAGNOSTIC VALUE OF P1NP,CTX-1, AND P1NP/CTX-1 RATIO IN PATIENTS WITH RHEUMATOID ARTHRITIS
Klinichescheskaya Laboratornaya Diagnostika, 2025
The value of fibroblast growth factor 21 in health and pathology
Yu. R. Akhverdyan, E. V. Papichev, B. V. Zavodovsky, Yu. V. Polyakova, L. E. Seewordova, E. S. Rozhkova
Siberian Journal of Clinical and Experimental Medicine, 2025
The article presents current ideas about the role of fibroblast growth factor 21 (FGF21) in the regulation of carbohydrate and lipid metabolism, as well as its contribution to the development of systemic inflammation in rheumatoid arthritis, both in laboratory animals and in humans. The classification of the fibroblast growth factor family, regulation of expression and receptor apparatus is considered. Positive effects of FGF21 have been noted in the form of normalization of carbohydrate and lipid metabolism, body weight; drugs analogues of FGF21 have proven themselves well as a therapeutic agent for the treatment of metabolic complications such as diabetes and fatty liver disease. At the same time, data are provided on the connection between elevated levels of FGF21 in blood serum and a number of pathological conditions, such as type 2 diabetes mellitus, coronary heart disease, obesity, non-alcoholic fatty liver disease, and end-stage renal failure. The facts about the controversial role of FGF21 against the background of systemic inflammation in patients with rheumatoid arthritis (RA) are reviewed. On the one hand, FGF21 may have a protective effect in patients with RA; on the other hand, serum FGF21 can be considered as a predictor of future decline in functional status and a potential marker for the progression of systemic inflammation in patients with RA. The prospects for using FGF21 for therapeutic purposes are assessed.
Analysis of the relationship between the composite body composition and the serum level of fibroblast growth factor 21 in female patients with rheumatoid arthritis
Siberian Medical Review, 2024
Association of serum chemerin levels with complications and comorbidity in rheumatoid arthritis
E. V. Papichev, Yu. R. Akhverdyan, Yu. V. Polyakova, L. E. Sivordova, B. V. Zavodovsky
Meditsinskiy Sovet, 2023
Introduction. Rheumatoid arthritis (RA) is a systemic autoimmune disease as well as a typical inflammatory process. Chemerin is a fat tissue cytokine, which specific receptors were discovered on the surface of the innate immune cells. It is of interest to study the association of chemerin with the complications and comorbidity in RA.Aim. To study the association between serum chemerin levels with complications and comorbidity in rheumatoid arthritis.Materials and methods. 88 women with RA were enrolled in our study. ll patients undergone standard clinical and laboratory examination. Serum chemerin, high-sensitive C-reactive protein (hsCRP), anti-citrullinated protein antibodies, insulin and C-peptide levels were determined using ELISA. X-ray absorptiometry was performed. Statistical analysis was performed using conventional methods with a software package Statistica 10.0.Results. Median chemerin concentration was 463.5 [366–576.5] ng/ml. Chemerin concentration correlated with the age (ρ = 0.232; р = 0.030), weight (ρ = 0.254; р = 0.017) and body mass index (BMI) (ρ = 0.212; р = 0.047), but wasn’t associated with the RA classification criteria. Positive correlation between chemerin concentration and number of painful joints (NPJ) (ρ = 0.213; р = 0.046) and hsCRP (ρ = 0.273; р = 0.010) was observed. Patients with type 2 diabetes mellitus (DM2) had higher chemerin concentration (598.0 ng/ml vs 479.5 ng/ml, Z = -2.68; p = 0.007) and patients with cholecystectomy in anamesis had lower (359.0 ng/ml vs 479.0 ng/ml, Z = 2.02; p = 0.043). Chemerin concentration correlated with systolic and diastolic blood pressure (BP) (ρ = -0.41; р < 0.001 and ρ = -0.27; р = 0.028, respectively).Conclusions. Chemerin concentration in women with RA correlates with age, weight, BMI, NPJ and hsCRP. Chemerin concentration in patients with comorbid DM2 was higher and in patients comorbid with cholecystectomy in anamnesis was lower. Chemerin concentration correlates negatively with a systolic and diastolic BP.
Advantages of zoledronic acid in the therapy of osteoporosis in real clinical practice
L. E. Sivordova, Yu. V. Polyakova, E. V. Papichev, Yu. R. Akhverdyan, B. V. Zavodovskii
Meditsinskiy Sovet, 2023
Introduction. The development of osteoporosis (OP) increases healthcare costs and often leads to disability of patients. In this regard, the search for ways to improve the effectiveness of OP treatment is very relevant. Today, there is a wide range of drugs for the effective correction of bone metabolism. However, low patient compliance in real clinical practice significantly reduces the effectiveness of therapy.Aim. To study the effect of patient compliance on the effectiveness of Zoledronic acid and Denosumab in OP in real clinical practice.Materials and methods. Study design: a retrospective analysis of outpatient records of 300 patients with OP, who were prescribed Zoledronic acid or Denosumab in 2019, with a prospective analysis of adherence to therapy for 3 years.Results. It was revealed that 12% of patients did not start pathogenetic therapy for OP (control group). 88% (264 patients) started pathogenetic therapy: of these, 22.33% (67 patients) preferred therapy with Denosumab; 65.67% (197 patients) – Zoledronic acid. After 1 year, therapy with Denosumab 19.4%, Zoledronic acid – 19.29% was discontinued. More than 1 month late with the next injection of the drug: Denosumab – 25.37%, Zoledronic acid – 16.24% of patients. Only 55.22% who received Denosumab and 64.47% who received Zoledronic acid fully complied with the recommendations. Most often, a violation of the schedule of drug administration was observed in patients over 75 years of age, alone, with impaired cognitive status. Discontinuation of therapy with Denosumab or violation of the schedule of its administration led to an increase in the level of bone resorption (C-telopeptide type I collagen (CTX-1)). During therapy with Zoledronic acid, there was no increase in CTX-1. In addition, the cost of course treatment with Zoledronic acid is 2–3 times less than with Denosumab.Conclusion. In real clinical practice, zoledronic acid has clinical and pharmacoeconomic advantages, especially in patients with expected low adherence to OP therapy.
Assessment of the quality of life of patients with gonarthrosis treated with a prosthesis of synovial fluid of domestic production
L. E. Sivordova, Yu. V. Polyakova, E. V. Papichev, Yu. R. Akhverdyan, B. V. Zavodovskii
Meditsinskiy Sovet, 2023
Introduction. Osteoarthritis (OA) is a chronic progressive disease of the joints, accompanied with pain, which limits the mobility of patients. Functional limitations, chronic pain syndrome worsen the quality of life (QoL) in OA of the joints of the lower extremities. QoL significantly depends on the effectiveness and methods of pain treatment, correction of functional disorders.Aim. Evaluation of the dynamics of QoL in patients with gonarthrosis treated with a high-tech synovial fluid prosthesis – sodium hyaluronate, domestic production.Materials and methods. The study group consisted of 50 patients who received intra-articular (IA) injections of domestically produced sodium hyaluronate (OOO Ingal, Russia). Comparison group – 30 patients treated with 2 ml of symptomatic drugs of delayed action (SYSADOA) (bioactive concentrate of small marine fish) administrated IA No. 5. Control group – 100 patients treated with a 1 ml of SYSADOA drugs administrated intramuscularly (IM) No. 20. Study program: 12 months, 6 visits with prospective monitoring of the quality of life of patients according to SF-36 compared with baseline data.Results. At the time of inclusion, patients had a similar level of physical and mental health components, which did not differ statistically significantly (p = 0.369 and p = 0.089). The study group demonstrated the best dynamics of the physical and mental components of health. The therapy was effective in all groups: most patients showed a statistically significant decrease in pain syndrome, an increase in QoL. The groups differed significantly in the speed of achieving the effect of pain relief, the severity of pain reduction and the duration of the effect of treatment.Conclusions. The spectrum of side effects of non-steroidal anti-inflammatory drugs (NSAIDs) does not allow their use for pain relief indefinitely. SYSADOAs become less effective in the progression of OA than in the early stages of the disease. The positive clinical effect of intra-articular injection of sodium hyaluronate solutions occurs faster and lasts longer than when using SYSADOA.
Рain syndrome in the shoulder joint. Clinical significance of bioactive concentrate of small seafish in real clinical practice
L. E. Sivordova, Yu. V. Polyakova, E. V. Papichev, Yu. R. Akhverdyan, B. V. Zavodovskii
Meditsinskiy Sovet, 2022
The limitation of the range of motion of the upper limb in combination with chronic pain syndrome and a decrease in the muscle strength of the arms leads to a significant deterioration in the quality of life of patients, often negatively affects their psychoemotional status, and reduces the ability to work. Arthrosis of the shoulder joint and pathology of the periarticular tissues of the shoulder affect up to 21% of the adult population and up to 33% of people over 60 years of age. Disagreements in the etiology, pathogenesis, terminology, approaches to the diagnosis and treatment of pain syndromes in the shoulder joint area do not contribute to the development of a unified concept of therapy for this pathology. The article provides a review of the literature on the epidemiology and pharmacotherapy of osteoarthritis and soft tissue pathology of the shoulder joint with an analysis of two clinical cases. The peculiarity of the first clinical case is the rapid achievement of therapeutic goals for third grade shoulder osteoarthrosis in an elderly patient with high comorbidity. This allows us to draw conclusions about the predominant role of periarticular tissues inflammation in the generation of severe pain syndrome. The second clinical case presents the dynamics of the development of calcifying tendinitis of the right, later of the left shoulder joint in a woman of working age. The use of a bioactive concentrate of small sea fish (BCSSF) (Alflutop®, Biotechnos) made it possible to quickly reduce the severity of the pain syndrome and return to the usual way of life in the first patient, which made it possible to shorten the use of non-steroidal anti-inflammatory drugs. In the second clinical example, BCSSF promoted the stimulation of regenerative processes in the periarticular tissues of the shoulder joint, the restoration of the function of the dominant limb and the ability to work. Thus, BCSSF may be the drug of choice for patients with osteoarthritis of the shoulder joints with a high risk of cardiovascular and gastrointestinal complications, as well as the drug of choice for a faster recovery of function in case of damage to the periarticular apparatus.
Risk factors for osteoporosis in patients with rheumatoid arthritis
Yu. R. Akhverdyan, E. V. Papichev, B. V. Zavodovsky, J. V. Polyakova, L. E. Seewordova
Sibirskij Nauchnyj Medicinskij Zhurnal, 2022
Aim of the study was to investigate risk factors for osteoporosis (OP) in patients with rheumatoid arthritis (RA). Material and methods. We observed 110 patients with a verified diagnosis of RA. RA was diagnosed based on the 2010 EULAR/ACR clinical classification. All patients with RA were divided into 2 groups: with ОP (53 patients) and without ОP signs (57 patients). Bone mineral density (BMD) was assessed by dual-energy X-ray densitometry (DEXA), the diagnosis was made on the basis of WHO recommendations. All patients underwent a standard clinical and laboratory examination, in addition the following parameters were studied: 25-OH vitamin D, C-terminal telopeptide of type I collagen (CTX-1), N-terminal propeptide of procollagen I (P1NP) content in the blood, the ratio of calcium to urine creatinine. Results. We found a statistically significant relationship between the presence of ОP and the following clinical signs: patient weight (р = 0.014), duration of RA course (р = 0.024), and the presence of erosive changes (р = 0.014). In addition, a relationship was found between the presence of OP and lower BMD in the Ward area (Ward) and the greater trochanter area (Troch) (р < 0.0001). It was also shown that taking glucocorticosteroid drugs for more than 3 months significantly increases the risk of developing ОP (р < 0.0001). Conclusions. Identification of risk groups for patients at risk for the development of OP is of great practical importance. The factors given in the article can be adjusted towards normalization in order to reduce the degree of possible risk, which is quite feasible in practice.
Clinical efficiency and safety of innovative synovial fluid prosthesis in the treatment of gonarthritis
L. E. Sivordova, J. V. Polyakova, E. V. Papichev, Y. R. Akhverdyan, B. V. Zavodovsky
Meditsinskiy Sovet, 2022
Introduction. Scientific discussions about ways to improve the effectiveness and safety of osteoarthritis (OA) therapy do not stop. The article discusses the most controversial issues of the problem and presents the results of a study on the use of sodium hyaluronate in gonarthrosis.Aim. To compare the clinical efficacy, tolerability and safety of the use of synovial fluid substitute of domestic manufacture and symptomatic slow-acting drugs (SYSADOA) in patients with gonarthrosis. Study design. Prospective, comparative, randomized, single center study. The duration of the study was 12 months.Materials and methods. The study included 180 patients with gonarthrosis, randomized into three groups. Study group: 50 patients treated with Ripart® sodium hyaluronate solution intra-articularly. Comparison group: 30 patients treated with SYSADOA, intraarticular. Control group: 100 patients treated with SYSADOA intramuscularly.Results. The most rapid and pronounced decrease in the VAS index was obtained during sodium hyaluronate therapy: by 31% at the 1st week, by 48% by the end of the 2nd week, with a maximum decrease by 49.1% by the 3rd month (p < 0.001). After 12 months, a lower level of the VAS index was observed: 32% lower than before the start of therapy (t = 47.23; p < 0.001). Comparable results were observed in this group in terms of the dynamics of the AUSCAN/WOMAC index. The effectiveness of therapy in the comparison and control groups was lower (p < 0.05). In addition, the use of sodium hyaluronate provided a significant reduction in the need for taking NSAIDs: 20 patients completely stopped taking NSAIDs (40%), 25 (50%) – they began to take NSAIDs less often or reduced the dose of drugs by 2 times, after 12 months they continued taking NSAIDs only 20% of patients in this group (p < 0.05).Сonclusions. Thus, Ripart® demonstrated high efficiency in reducing pain, contributed to a significant reduction in the need for NSAIDs in patients with gonarthrosis, and has a good safety profile.
Menopause and rheumatoid arthritis as factors associated with osteoporosis development
, E.V. Papichev, J.V. Polyakova, , Yu.R. Akhverdyan, , L.E. Sivordova, , B.V. Zavodovsky, and
Siberian Medical Review, 2022
The aim of the research. To study the role of menopause, glucocorticoids (GCs) intake and characteristics of rheumatoid arthritis (RA) in development of osteoporosis (OP) and osteoporotic fractures. Material and methods. A total of 73 female RA patients in menopause were examined. The control group included 29 female RA patients in premenopause. In addition to standard clinical and laboratory examinations, P1NP, 25(OH)D, CTX-1 were measured, dual-energy x-ray absorptiometry and x-ray of the thoracic and lumbar spine were performed. Statistical analysis was performed using the “Statistica 12.0” software package. Results. Premenopausal patients had lower BMI. Patients in postmenopause had higher rate of OP (42 patients) than the controls (8 patients) (57.5% vs 27.6%, respectively). Among patients in postmenopause, OP was associated with lower BMI (27.6 vs 30.5 kg/m2), higher cumulative dose of GCs (6.9 vs 1.65 g), higher duration of GCs intake (32 vs 18 months), lower RA activity (3.37 vs 3.9 according to DAS28-CRP) and lower CTX-1 level (0.52 vs 0.7 ng/ml). In the same group, osteoporotic fractures were only associated with longer GCs intake (32 vs 24 months). In premenopause patients, OP was associated with longer RA duration (21 vs 6 months), cumulative dose of GCs (13.9 vs 0.45 g), duration of GCs intake (48 vs 3 months), higher level of hs-CRP (46 vs 8 mg/l) and lower P1NP level (51.8 vs 43.8 ng/ml). Osteoporotic fractures in premenopause were associated with RA duration (28 vs 6 months), cumulative dose of GCs (12.5 vs 1.2 g) and lower BMD in all examined areas. Conclusion. The OP rate was higher in postmenopause patients. In both groups, the duration of GCs intake and accumulated dose of GCs were associated with OP. In postmenopause, OP was also associated with lower BMI. In premenopause, OP and osteoporotic fractures were associated with longer RA duration, cumulative dose of GCs and lower BMD in all studied areas.
Comparative characteristics of the level of highly sensitive C-reactive protein in patients with systemic lupus erythematosus and rheumatoid arthritis
Yu. R. Akhverdyan, B. V. Zavodovsky, Yu. V. Polyakova, L. E. Seewordova, E. V. Papichev
Sibirskij Nauchnyj Medicinskij Zhurnal, 2021
Investigation of clinical and laboratory manifestations of rheumatoid arthritis depending on the level of serum fetuin-a
Siberian Medical Review, 2021
Modern facilities of pharmacological correction of hyperuricemia in rheumatic diseases: Management of difficult clinical cases
L. E. Sivordova, Yu. V. Polyakova, E. V. Papichev, Yu. R. Akhverdyan, B. V. Zavodovskii
Meditsinskiy Sovet, 2021
Clinical significance of collchicine in pharmacotherapy of cardiovascular pathology in patients with hyperuricemia in rheumatic diseases
L. E. Sivordova, J. V. Polyakova, E. V. Papichev, Y. R. Akhverdyan, B. V. Zavodovskii
Meditsinskiy Sovet, 2021
Study of risk factors for the osteoporosis development in Rheumatoid arthritis in real clinical practice
E. V. Papichev, Yu. R. Akhverdyan, Yu. V. Polyakova, L. E. Sivordova, B. V. Zavodovskii
Meditsinskiy Sovet, 2021
Prediction of osteoporosis severity in patients with rheumatoid arthritis via evaluation of the Fetuin-A level
, Yu.R. Akhverdyan, E.V. Papichev, , B.V. Zavodovsky, , Ju.V. Polyakova, , L.E. Polyakova, and
Siberian Medical Review, 2021
Assessment of the safety, tolerability and effectiveness of first Russian generic aceclofenac in patients with undifferentiated peripheral inflammatory arthritis
B. V. Zavodovsky, L. E. Sivordova, Yu. V. Polyakova, Yu. R. Akhverdyan, E. V. Papichev
Terapevticheskii Arkhiv, 2020
Body composition and serum fetuin-A levels in patients with rheumatoid arthritis
Б.В. Заводовский, Л.Е. Сивордова, Ю.Р. Ахвердян, Ю. В. Полякова, E. Papichev, B. Zavodovsky, L. Sivordova, Y. Akhverdyan, Y. Polyakova, I. Zborovskaya
Sibirskij Nauchnyj Medicinskij Zhurnal, 2020
FETUIN-A AND SECONDARY OSTEOPOROSIS IN PATIENTS WITH RHEUMATOID ARTHRITIS
Evgeniy V. Papichev, Boris V. Zavodovsky, Larisa E. Seewordova, Yuriy R. Akhverdyan, Yuliya V. Polyakova
I P Pavlov Russian Medical Biological Herald, 2019
Serum fetuin-A levels in patients with rheumatoid arthritis
E. V. Papichev, B. V. Zavodovsky, L. E. Sivordova, Yu. R. Akhverdyan, Yu. V. Polyakova
Nauchno Prakticheskaya Revmatologiya, 2019
Rheumatoid arthritis in real clinical practice: initiation of therapy with biological agents. Results of the «Computer Terminals of Self-Assessment for Patients with Rheumatic Diseases» («TERMINAL-II») project
V. N. Amirdzhanova, E. Yu. Pogozheva, A. E. Karateev, O. V. Antipova, I. B. Vinogradova, A. Yu. Kazankova, R. G. Mukhina, A. G. Vasilyev, O. B. Nesmeyanova, E. A. Bogdanova, R. R. Samigullina, A. A. Vasilenko, I. B. Bashkova, T. S. Salnikova, I. N. Dashkov, N. E. Nikulenkova, V. Yu. Manokhin, I. P. Afanasyeva, O. N. Anoshenkova, T. V. Plaksina, M. R. Spitsina, L. V. Solodovnikova, A. V. Petrov, O. P. Slyusar, E. V. Papichev, E. V. Ivanova, L. V. Masneva, L. P. Evstigneeva, I. V. Kolotilina, E. N. Otteva, I. A. Cherentsova, I. N. Shchendrygin, S. A. Derevenskikh, I. G. Bannikova, N. K. Delyavskaya, I. N. Danilova, I. M. Marusenko
Sovremennaya Revmatologiya, 2019
Fetuin A.Novel hepatokine in rheumatoid arthritis laboratory diagnostics
E. Papichev, B. Zavodovsky, Y. Polyakova, L. Seewordova, Y. Akhverdyan
Klinichescheskaya Laboratornaya Diagnostika, 2018

Evgeniy Vasilievich Papichev

EDUCATION

RESEARCH, TEACHING, or OTHER INTERESTS

Scopus Publications